Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00247650 | Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy | PHASE2 | COMPLETED | 190 | — | — | Sep 1, 2005 | - | Mar 1, 2017 | 10 | Canada |
| Name | Type | Description |
|---|---|---|
| Zoledronic Acid; Letrozole | DRUG | - |
Inclusion Criteria * Postmenopausal women * Newly diagnosed with non metastatic breast cancer * Candidate for mastectomy or breast-conserving surgery Exclusion Criteria * Patients with invasive tumors * Patients receiving anti-cancer treatment * Patients who have undergone surgery Other protocol...